Skip to main navigation Skip to search Skip to main content

A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial

  • University Hospitals Plymouth NHS Trust

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Liver surgery (LS) remains the main curative option for liver metastases and primary liver tumours. Low-calorie and very low-calorie diets (VLCDs) are routinely used for 2-4 weeks prior to bariatric and gallbladder surgery to reduce liver size and abdominal adiposity, thereby improving surgical safety. This study aimed to evaluate the feasibility of a VLCD in patients undergoing LS with hepatic steatosis (HS).
Methods
In this randomised controlled feasibility trial, 29 participants were randomised to either the intervention group (VLCD providing 800 kcal and 80 g protein for 2 weeks before LS; n = 14) or treatment as usual (n = 15). Feasibility and clinical outcomes, including operating time, blood loss, ease of surgery, length of hospital stay, readmission and mortality, were assessed.
Results
There was no indication of a between-group difference. There was no mortality within 90 days. In the intervention group, 11 participants initiated VLCD and 6 adhered to it for at least 10 days.
Discussion
Although this feasibility study did not demonstrate a clinical benefit due to the small sample size, a definitive trial is needed to evaluate whether a VLCD administered 2 weeks before LS reduces HS during the preoperative period.
Original languageEnglish
Article number111504
JournalEuropean Journal of Surgical Oncology
Volume52
Issue number4
Early online date2 Mar 2026
DOIs
Publication statusPublished - Apr 2026

ASJC Scopus subject areas

  • Surgery
  • Oncology

Keywords

  • Hepatic steatosis
  • Liver metastases
  • Liver surgery
  • Liver tumour
  • Low-calorie diet

Fingerprint

Dive into the research topics of 'A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial'. Together they form a unique fingerprint.

Cite this